PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Loss of PTEN expression is associated with shorter median survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate.

Bibliographic Details
Main Authors: Ferraldeschi, Roberta, Nava Rodrigues, Daniel, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rescigno, Pasquale, Ravi, Praful, Pezaro, Carmel, Omlin, Aurelius, Lorente, David, Zafeiriou, Zafeiris, Mateo, Joaquin, Altavilla, Amelia, Sideris, Spyridon, Bianchini, Diletta, Grist, Emily, Thway, Khin, Perez Lopez, Raquel, Tunariu, Nina, Parker, Chris, Dearnaley, David, Reid, Alison, Attard, Gerhardt, de Bono, Johann
Format: Online
Language:English
Published: Elsevier Science 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410287/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410287/

Similar Items